Ahead of the ASCO Annual Meeting, we discuss the use of germline testing and PARP inhibitors in patients with breast cancer with Jennifer K. Litton, MD.
Jennifer K. Litton, MD
Advertisement
Articles by Jennifer K. Litton, MD
Collaboration between oncologists and reproductive endocrinologists/infertility specialists not only will improve patient care, but it also will facilitate advances in the field through cooperative research and education.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Achieving a “Functional Cure” With Multiple Myeloma Therapy
2
ASCO Updates 340B Policy Statement to Expand Access, Improve Transparency
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study
5